Rachel E Sanborn - JoVE Visualize

Showing results (21-30 of 65) with videos related to

Pageof 7

Sort By:

Oncoimmunology|May 13, 2026

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.

Clinical Lung Cancer|February 19, 2013

Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinomaDerick H M Lau, James Moon, Angela M Davies, et al.

The Lancet. Oncology|February 10, 2016

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.

Lung Cancer (Amsterdam, Netherlands)|July 20, 2012

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerChristelle Clément-Duchêne, Ronald B Natale, Thierry Jahan, et al.

Clinical Lung Cancer|March 17, 2020

Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based ChemotherapySusanne M Arnold, Kari Chansky, Maria Q Baggstrom, et al.

American Journal of Clinical Oncology|May 22, 2018

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal CancerEmerson Y Chen, Charles D Blanke, Daniel G Haller, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.

Journal for Immunotherapy of Cancer|July 24, 2021

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.

Journal for Immunotherapy of Cancer|December 21, 2017

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancerRachel E Sanborn, Helen J Ross, Sandra Aung, et al.

JTO Clinical and Research Reports|February 8, 2024

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic TumorsKathryn E Beckermann, Christine M Bestvina, Badi El Osta, et al.

Pageof 7

Showing results (21-30 of 65) with videos related to

Sort By:

Pageof 7

Oncoimmunology|May 13, 2026

Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.

Clinical Lung Cancer|February 19, 2013

Southwestern oncology group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinomaDerick H M Lau, James Moon, Angela M Davies, et al.

The Lancet. Oncology|February 10, 2016

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b studyScott Antonia, Sarah B Goldberg, Ani Balmanoukian, et al.

Lung Cancer (Amsterdam, Netherlands)|July 20, 2012

A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancerChristelle Clément-Duchêne, Ronald B Natale, Thierry Jahan, et al.

Clinical Lung Cancer|March 17, 2020

Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based ChemotherapySusanne M Arnold, Kari Chansky, Maria Q Baggstrom, et al.

American Journal of Clinical Oncology|May 22, 2018

A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal CancerEmerson Y Chen, Charles D Blanke, Daniel G Haller, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021

Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor MalignanciesMelissa Johnson, Anthony El-Khoueiry, Navid Hafez, et al.

Journal for Immunotherapy of Cancer|July 24, 2021

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding studyRachel E Sanborn, Omid Hamid, Elisabeth Ge de Vries, et al.

Journal for Immunotherapy of Cancer|December 21, 2017

A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancerRachel E Sanborn, Helen J Ross, Sandra Aung, et al.

JTO Clinical and Research Reports|February 8, 2024

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic TumorsKathryn E Beckermann, Christine M Bestvina, Badi El Osta, et al.

Pageof 7